Drug Trial Radar · NCT04261075
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Aug 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Mar 3, 2020
Primary completion
Jun 16, 2022
Study completion Jun 16, 2022
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 101 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability and to determine the dose of IPH5201 that can be used as monotherapy or in combination with durvalumab +/- oleclumab in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
IPH5201Biological
Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
durvalumabBiological
Durvalumab Q3W for a maximum of 2 years
oleclumabBiological
Oleclumab Q3W for a maximum of 2 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events as a measure of safetyTime frame: From time of informed consent through treatment period and including the follow-up 12 weeks after last dose of investigational product, approximately 7 months
- Incidence of clinically significant laboratory values as a measure of safetyTime frame: From time of informed consent through 12 weeks after the last dose of investigational product, approximately 7 months
- Incidence of clinically significant electrocardiogram (ECG) abnormalities as a measure of safetyTime frame: From time of informed consent through treatment period and including the follow-up period 12 weeks after last dose of investigational product, approximatley 7 months
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Huntersville, North Carolina
Research Site
Providence, Rhode Island
Research Site
Nashville, Tennessee
Research Site
Bordeaux, France
Research Site
Villejuif, France
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Lausanne, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.